Dual ATP and pH responsive ZIF-90 nanosystem with favorable biocompatibility and facile post-modification improves therapeutic outcomes of triple negative breast cancer in vivo

Jiang, Zhenqi; Wang, Yinjie; Sun, Li; Yuan, Bo; Tian, Yuchen; Xiang, Lingchao; Li, Yanying; Li, Yong; Li, Juan; Wu, Aiguo

doi:10.1016/j.biomaterials.2019.01.001

Cited by 165 publications

(117 citation statements)

References 56 publications

Supporting

Mentioning

104

Contrasting

Unclassified

Order By: Relevance

“…This phenomenon was due to the partially compromised ligand–metal coordination, and a similar trend was also observed in drug encapsulation by other types of nanocarriers . All three types of nanocarriers showed a slightly positive surface charge, which was consistent with previous report (Figure B) . The transmission electron microscopy (TEM) analysis of the particles was consistent with the dynamic light scattering results and all samples displayed uniform spherical morphology (Figure C,D; Figure S1, Supporting Information).…”

Section: Resultssupporting

confidence: 89%

Energy‐Free, Singlet Oxygen‐Based Chemodynamic Therapy for Selective Tumor Treatment without Dark Toxicity

Chen

Deng

Liu

et al. 2019

Adv Healthcare Materials

View full text Add to dashboard Cite

Traditional singlet oxygen‐based antitumor therapies have been burdened with the necessity of external energy (e.g., light and ultrasound) and harmful dark toxicity. Ascorbate at the pharmacological concentration could accumulate hydrogen peroxide only in the tumor site. It is postulated that the concurrent delivery of ascorbate and nanoparticulate hypochlorous ion (ClO−) could produce singlet oxygen at the tumor site as an energy‐free, tumor‐specific therapy. The ClO− is loaded in a hybrid core–shell nanocarrier consisting of a zeolitic imidazolate framework and amphiphilic poloxamer 188. Intracellular singlet oxygen production is verified in 4T1 cells by the cooperation between hybrid nanocarriers and ascorbate, which induces significant apoptotic cell death. Upon intravenous nanocarriers delivery plus intraperitoneal ascorbate administration to xenograft mice, the in vivo antitumor efficacy of this cooperative nanomedicine is demonstrated without noticeable side‐effects. This work demonstrates a proof‐of‐concept of singlet oxygen‐based chemodynamic therapy for selective tumor eradication, which produces a novel trigger‐free, singlet oxygen‐based cancer therapy without the side effects of traditional photodynamic and sonodynamic therapy.

show abstract

Section: Resultssupporting

confidence: 89%

Energy‐Free, Singlet Oxygen‐Based Chemodynamic Therapy for Selective Tumor Treatment without Dark Toxicity

Chen

Deng

Liu

et al. 2019

Adv Healthcare Materials

View full text Add to dashboard Cite

show abstract

“…As shown in Figure a,b, GdSalNPs10 shows low but detectable Gd 3+ release in PBS and FBS with different pH values. It is only 1.4% of Gd 3+ released from GdSalNPs10 at 72 h in pH 7.4 of PBS with a spike of 10% FBS to simulate the liquid environment in vivo 31. With a decrease in the pH value of the release medium, the Gd 3+ release from GdSalNPs10 was slightly faster at pH 6.0 and 4.5, which are about 3.7% and 5.0% at 72 h, respectively.…”

Section: Resultssupporting

confidence: 60%

Ten‐Gram‐Scale Facile Synthesis of Organogadolinium Complex Nanoparticles for Tumor Diagnosis

Wei

Jiang

Pan

et al. 2020

Small

Self Cite

View full text Add to dashboard Cite

The market of available contrast agents for clinical magnetic resonance imaging (MRI) has been dominated by gadolinium (Gd) chelates based T1 contrast agents for decades. However, there are growing concerns about their safety because they are retained in the body and are nephrotoxic, which necessitated a warning by the U.S. Food and Drug Administration against the use of such contrast agents. To ameliorate these problems, it is necessary to improve the MRI efficiency of such contrast agents to allow the administration of much reduced dosages. In this study, a ten‐gram‐scale facile method is developed to synthesize organogadolinium complex nanoparticles (i.e., reductive bovine serum albumin stabilized Gd‐salicylate nanoparticles, GdSalNPs‐rBSA) with high r1 value of 19.51 mm−1 s−1 and very low r2/r1 ratio of 1.21 (B0 = 1.5 T) for high‐contrast T1‐weighted MRI of tumors. The GdSalNPs‐rBSA nanoparticles possess more advantages including low synthesis cost (≈0.54 USD per g), long in vivo circulation time (t1/2 = 6.13 h), almost no Gd3+ release, and excellent biosafety. Moreover, the GdSalNPs‐rBSA nanoparticles demonstrate excellent in vivo MRI contrast enhancement (signal‐to‐noise ratio (ΔSNR) ≈ 220%) for tumor diagnosis.

show abstract

“…This might be attributed to the fact that ATP has a stronger metal coordination ability than porphyrin. [ 50,51 ] Thus, we further explored the drug release behavior of RES@PCN in the presence of ATP. As shown in Figure 1E, less than 20% of RES was released in the group without ATP, avoiding the side effects of RES leakage.…”

Section: Resultsmentioning

confidence: 99%

A Mitochondria‐Driven Metabolic Sensing Nanosystem for Oxygen Availability and Energy Blockade of Cancer

Wan

Liu

Cheng

et al. 2020

Advanced Therapeutics

View full text Add to dashboard Cite

A mitochondrial targeting and adenosine triphosphate (ATP)‐responsive nanosystem is designed and constructed to interfere with mitochondrial respiration. This triggers metabolic therapy and enhanced photodynamic therapy of malignant tumor via blocking of ATP and the diversion of endogenous oxygen. The nanosystem is synthesized by incorporating the drug resveratrol (RES) into porous coordination polymer PCN‐224 (RES@PCN). After RES@PCN nanoparticles target the tumor site by enhanced penetration and retention (EPR) effects, PCN delivery endows RES@PCN nanoparticles with the ability to target mitochondria. Subsequently, ATP overexpressed in the mitochondria of tumor cell disintegrates the PCN structure by coordination substitution. This also leads to release of entrapped drug RES. As an ATPase inhibitor, RES interferes with the metabolism of the respiratory chain of tumor cell, triggering an ATP‐blocked metabolic therapy. In addition, inhibition of mitochondrial respiration reduces the consumption of endogenous oxygen. The spare oxygen is used as an “oxygen depot” in photodynamic therapy for generation of toxic reactive oxygen species. Taken together, the mitochondria‐driven metabolic interference system successfully achieves synergistic photodynamic and metabolic therapy via a respiratory inhibition‐medicated oxygen diversion and an ATP blockade. This strategy has great potential for cancer treatment.

show abstract

Dual ATP and pH responsive ZIF-90 nanosystem with favorable biocompatibility and facile post-modification improves therapeutic outcomes of triple negative breast cancer in vivo

Cited by 165 publications

References 56 publications

Energy‐Free, Singlet Oxygen‐Based Chemodynamic Therapy for Selective Tumor Treatment without Dark Toxicity

Energy‐Free, Singlet Oxygen‐Based Chemodynamic Therapy for Selective Tumor Treatment without Dark Toxicity

Ten‐Gram‐Scale Facile Synthesis of Organogadolinium Complex Nanoparticles for Tumor Diagnosis

A Mitochondria‐Driven Metabolic Sensing Nanosystem for Oxygen Availability and Energy Blockade of Cancer

Contact Info

Product

Resources

About